TrialID,"Last Refreshed on","Public title","Scientific title",Acronym,"Primary sponsor","Date registration","Date registration3","Export date","Source Register","web address","Recruitment Status","other records","Inclusion agemin","Inclusion agemax","Inclusion gender","Date enrollement","Target size","Study type","Study design",Phase,Countries,"Contact Firstname","Contact Lastname","Contact Address","Contact Email","Contact Tel","Contact Affiliation","Inclusion Criteria","Exclusion Criteria",Condition,Intervention,"Primary outcome","Secondary outcome","results date posted","results date completed","results url link","Retrospective flag","Bridging flag truefalse","Bridged type","results yes no"
IRCT20160307026950N6,"11 September 2018","Comparison of low dose midazolam and etomidate for the Prevention of myoclonic Movements following etomidate Injection.","Comparison of the Effects of Low-Dose Midazolam and Low-Dose etomidate on Prevention of Etomidate-Induced Myoclonus in electroconvulsive therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",,"Esfahan University of Medical Sciences",03/07/2018,"  20180703","03/03/2024 20:27:40",IRCT,http://en.irct.ir/trial/22210,"Not Recruiting",No,"9 years","15 years",Both,22/06/2017,120,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients are randomly assigned to three groups A, B, C, using the Random Allocation computer software, Blinding description: All drugs are in one form and in the form of a volume in the syringe by the researcher, and the hemodynamic changes are monitored and recorded, so the attending and the clinical caregiver and the evaluator do not understand the type of medication.",3,"Iran (Islamic Republic of)","Seyedeh Maryam Mousavi",,Charbaghbala,smmousavi717@gmail.com,"+98 313372373","Esfahan University of Medical Sciences","Inclusion criteria: All Patients candidate  Electroconvulsive Therapy<br>ASA I,ASAII<br>Age 6 - 15 years","Exclusion criteria: Severe cardiovascular disease<br>kidney disease<br>Liver disease<br>Chronic respiratory disease<br>drugs Allergy<br>discontinue of cooperation<br>intubation","Myoclonic Movements.","Intervention 1: Intervention group: . Intervention 2: Intervention group: . Intervention 3: Control group: .","Myoclonus. Timepoint: After induction anesthesia. Method of measurement: Observation of  myoclonic movements (0,1,2,3).;Heart rate changes. Timepoint: Before the intervention,  then after the intervention, , 5, 10, 20 minutes after intervention and then After The discharge  time of recovery. Method of measurement: Pulse oximetry device.;Mean arterial blood pressure. Timepoint: Before the intervention,  then after the intervention, , 5, 10, 20 minutes after intervention and then After The discharge  time of recovery. Method of measurement: non invasive  blood pressure.;Oxygen saturation. Timepoint: Before the intervention,  then after the intervention, , 5, 10, 20 minutes after intervention and then After The discharge  time of recovery. Method of measurement: Pulse oximetry device.;Duration of seizure. Timepoint: After intervention. Method of measurement: In seconds using a chronometer.;Recovery Duration. Timepoint: Since entering the recovery section until discharge time. Method of measurement: Minute with using a chronometer.","Nausea and Vomiting. Timepoint: During the stay in the recovery. Method of measurement: In minutes using the chronometer.;Headache. Timepoint: During the stay in the recovery. Method of measurement: Ask the patient about this complication.;Muscle Pain. Timepoint: During the stay in the recovery. Method of measurement: Ask the patient about this complication.",,,,No,False,"          ",
IRCT20130812014333N95,"16 July 2018","Electroconvulsive therapy and Parkinson","Effect of electroconvulsive therapy on motor and psychiatric symptoms of drug-resistant Parkinson's patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",,"Kermanshah University of Medical Sciences",15/06/2018,"  20180615","03/03/2024 20:27:40",IRCT,http://en.irct.ir/trial/31592,Recruiting,No,"40 years","75 years",Both,19/06/2016,16,interventional,"Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.",2-3,"Iran (Islamic Republic of)","Jaza Rahkan",,"Eidar Square, Dolatabad Boulevard, Farabi Hospital",pjsrahkan@yahoo.com,"+98 83 3826 1046","Kermanshah University of Medical Sciences","Inclusion criteria: Parkinson's patients with motor and psychiatric symptoms resistant to drug therapy<br>Age between 40 and 75 years","Exclusion criteria: Cardiovascular patients; Patients with cognitive impairment; Patients with the history of seizure, stroke","Parkinson. <br>Parkinson's disease","The intervention group in addition to dopaminergic medications, will receive a 25-julestwo-sided frontotemporal ectoplasmic twice a week.If the person does not get seizure, the next stimulus is performed at 50, 75, 100 jules.During this stage of anesthesia we can induce seizures up to 4 times.","Motor symptoms. Timepoint: At the beginning of the study, the end of the sixth week and one month after the end of the study. Method of measurement: Using the Unified Parkinson's disease rating scale (UPDRS).;Psychiatric symptoms. Timepoint: At the beginning of the study, the end of the sixth week and one month after the end of the study. Method of measurement: Using the Brief Psychiatric Rating Scale (BPRS).",,,,,No,False,"          ",
